An acquisition in the biosimilars space was the biggest deal announced in biopharma M&A during March.
Licensing agreements and other collaborations continue to account for most of the activity in the deal-making space as March mirrored February as a quiet month on the acquisitions front.
As well as Formycon's (LON: OW4N) purchase of biosimilar assets from ATHOS KG, acquisitions that were announced included the latest special purpose acquisition company (SPAC) deal and another buy by Fujifilm Holdings (TYO: 4901).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze